Drug-resistant epilepsy — time to target mechanisms

Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options

(2020) Wolfgang Löscher et al.   PHARMACOLOGICAL REVIEWS

Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome

(2020) Zhou Han et al.   Science Translational Medicine

Therapeutic strategies for glucose transporter 1 deficiency syndrome

(2019) Maoxue Tang et al.   Annals of Clinical and Translational Neurology

Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs

(2018) Zhibin Chen et al.   JAMA Neurology

Epilepsy

(2018) Orrin Devinsky et al.   Nature Reviews Disease Primers

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

(2016) Jacqueline A French et al.   LANCET

Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug

(2014) Anna Doeser et al.   BRAIN

Ion channels in genetic and acquired forms of epilepsy

(2012) Holger Lerche et al.   JOURNAL OF PHYSIOLOGY-LONDON

Optogenetic and Potassium Channel Gene Therapy in a Rodent Model of Focal Neocortical Epilepsy

(2012) R. C. Wykes et al.   Science Translational Medicine